Abstract
BackgroundChimeric antigen receptor (CAR) T cells have demonstrated high clinical response rates against hematological malignancies (e.g., CD19+ cancers) but have shown limited activity in patients with solid tumors. Recent work...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have